Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ADP-ribosylserine hydrolase (ARH3) is an enzyme of the ADP-ribosylglycohydrolase family, specializing in the removal of ADP-ribose modifications from serine residues on proteins, primarily in the context of DNA damage response. It hydrolyzes the alpha-O-linkage at the anomeric C1'' position of ADP-ribose in proteins, free poly(ADP-ribose), and O-acetyl-ADP-D-ribose, but does not act on ADP-ribosylation at arginine, cysteine, diphthamide, or asparagine. The main physiological roles include safeguarding cells from poly(ADP-ribose)-induced cell death (parthanatos), supporting DNA repair, and contributing to genomic stability. Its function is distinct from related hydrolases such as ARH1 or PARG in substrate specificity and activity. Dysfunction of ARH3 has been implicated in neurodegenerative pathology due to accumulation of toxic ADP-ribose polymers, emphasizing its therapeutic potential and highlighting safety concerns for direct inhibition.
For potential inhibitors—block enzymatic hydrolysis of ADP-ribosyl-serine; interfere with removal of ADP-ribose modifications, modulating DNA repair and programmed cell death.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ADP-ribosylserine hydrolase (ARH3).